Introduction of Dingtai Pharmaceutical
Hebei Dingtai Pharmaceutical Co., Ltd. was established in 2017 and is a wholly-owned subsidiary of Beijing Tide Pharmaceutical Co., Ltd. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. The company is mainly engaged in the production and sales of APIs and intermediates, and is engaged in the R&D, technical cooperation, technical consultation, and technology transfer of APIs and intermediates.
The construction site of this project is Cangzhou Lingang Economic and Technological Development Zone. The construction period of the first phase is 3 years (November 2018 ~ June 2021). After the completion of the project, it will become the raw material drug production base of Zhengda Pharmaceutical Group. The products include two parts: a class of innovative drugs with global independent intellectual property rights and high-end generic drugs with technical barriers. The company's business involves multiple major indications such as oncology, pain, respiratory, cardiovascular, etc., it is mainly to provide raw materials and intermediates for global new original drugs or generic drugs with high technical barriers, it is to open up blank markets at home and abroad, and provide preferred The medication plan has benefited hundreds of millions of patients.
The total investment of the project is 650 million yuan, the first phase investment is 388 million yuan, and the total construction area is about 45,000 square meters. Among them, the production workshop area is about 13,000 square meters, with multiple production lines; the building area for auxiliary functions such as quality inspection office, storage, and power is about 32,000 square meters.